FDA's Expanded Access and Compassionate Use Rules' Impact on Mesothelioma Treatment

Adnan Jaigirdar, MD, FACS, provided an overview of the U.S. Food and Drug Administration (FDA) expanded access program (compassionate use) for investigative therapies for mesothelioma patients.